Christopher Bunka - Lexaria Bioscience Chairman
Chairman
Mr. Christopher A. Bunka is Chairman of the Board, Chief Executive Officer of Lexaria Corporationration, Mr. Bunka is no longer President of the Company. He has completed both equity and debt financings for company, completed the acquisition of additional oil gas assets, disposed of other oil gas assets, and restructured company. He has refocused company from one of natural gas exploration to that of development of existing oil reserves, and has engaged additional geophysical in an attempt to better understand its exploration and development opportunities. Mr. Bunka has privately evaluated numerous oil and gas properties and investment opportunities for his private investments during the past 10 years. Since 1988, Mr. Bunka was the CEO of CAB Financial Services Ltd., a private holding company located in Kelowna, Canada. He is a VCist and corporate consultant. From 1999 to 2002, Mr. Bunka was the President and CEO of Secure Enterprise Solutions . The Company subsequently changed its name to Edgetech Services and traded on the OTC with the symbol EDGH. Newsgurus.com was a webbased media company. Secure Enterprise Solutions moved into Internetbased computer security products and services and was subsequently purchased by Edgetech Services. Mr Bunka is also ChairmanCEO of Enertopia Corporationration a clean energy company. Mr. Bunka is a director of Defiance Capital Corporationration, a Canadian resource company. since 2017.
| Age | 51 |
| Tenure | 7 years |
| Phone | 250 765 6424 |
| Web | http://www.lexariabioscience.com |
Christopher Bunka Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Bunka against Lexaria Bioscience otc stock is an integral part of due diligence when investing in Lexaria Bioscience. Christopher Bunka insider activity provides valuable insight into whether Lexaria Bioscience is net buyers or sellers over its current business cycle. Note, Lexaria Bioscience insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lexaria Bioscience'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Bunka 2 days ago Acquisition by Christopher Bunka of 6500 shares of Lexaria Bioscience at 0.201 subject to Rule 16b-3 | ||
Christopher Bunka over three weeks ago Acquisition by Christopher Bunka of 21900 shares of Lexaria Bioscience at 1.988 subject to Rule 16b-3 |
Lexaria Bioscience Management Efficiency
The company has return on total asset (ROA) of (87.72) % which means that it has lost $87.72 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (164.27) %, meaning that it created substantial loss on money invested by shareholders. Lexaria Bioscience's management efficiency ratios could be used to measure how well Lexaria Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 156.1 K in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Lexaria Bioscience Corp has a current ratio of 8.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Lexaria Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Lexaria Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lexaria Bioscience Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lexaria to invest in growth at high rates of return. When we think about Lexaria Bioscience's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Fred Lampropoulos | Merit Medical Systems | 74 | |
| Michael Hartnett | RBC Bearings Incorporated | 78 | |
| William Daley | Bank of New | 70 | |
| Reginald Newman | Rand Capital Corp | 78 | |
| Franco Stevanato | Stevanato Group SpA | 51 | |
| Joseph Echevarria | Bank of New | 64 | |
| Rakesh Sachdev | RBC Bearings Incorporated | 64 | |
| Charles Scharf | Bank of New | 52 | |
| Gerald Hassell | Bank of New | 64 | |
| Curtis Arledge | Bank of New | 49 | |
| Brian Shea | Bank of New | 55 | |
| Mark Gliebe | RBC Bearings Incorporated | 56 | |
| Robin Vince | Bank of New | 52 | |
| Hani Kablawi | Bank of New | 52 | |
| Thomas Gibbons | Bank of New | 64 | |
| Edward Ross | Fidus Investment Corp | 58 | |
Management Performance
| Return On Equity | -164.27 | |||
| Return On Asset | -87.72 |
Lexaria Bioscience Corp Leadership Team
Elected by the shareholders, the Lexaria Bioscience's board of directors comprises two types of representatives: Lexaria Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lexaria. The board's role is to monitor Lexaria Bioscience's management team and ensure that shareholders' interests are well served. Lexaria Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lexaria Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicholas Baxter, Director and Member of Audit Committee | ||
| Christopher Bunka, Chairman, CEO, Secretary and Member of Audit Committee | ||
| Allan Spissinger, Acting CFO, Treasurer, Secretary | ||
| Ted McKechnie, Director | ||
| Ed Ergenzinger, Chief Legal Officer and Senior Vice President - Innovation | ||
| John Docherty, President |
Lexaria Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Lexaria Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -164.27 | |||
| Return On Asset | -87.72 | |||
| Current Valuation | 21.27 M | |||
| Shares Outstanding | 89.59 M | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 0.11 % | |||
| Price To Earning | (13.00) X | |||
| Price To Book | 8.99 X | |||
| Price To Sales | 48.33 X | |||
| Revenue | 384.54 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lexaria Bioscience in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lexaria Bioscience's short interest history, or implied volatility extrapolated from Lexaria Bioscience options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Lexaria OTC Stock
If you are still planning to invest in Lexaria Bioscience Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lexaria Bioscience's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |